Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results.

摘要: Background: Bevacizumab is a recombinant humanized monoclonal antibody that obstructs the vascular endothelial growth factor (VEGF) pathway. Despite its extensive employment in treatment of primary tumors brain, experience brain metastatic disease, frequent complication patients with lung cancer, very limited. On basis strong antiedemigenous effect and no risk intracranial bleeding, we administered bevacizumab-based chemotherapy to non-small-cell cancer (NSCLC) symptomatic lesions who were not suitable candidates for specific local therapy. Methods: The received bevacizumab 7.5 mg/kg cisplatin 75 mg/m2 on day 1, gemcitabine 1,250 days 1 8, every 21 days. Results: We studied 13 clinical radiological progressive metastases; majority had treatment-naive disease. Bevacizumab-based was found be well tolerated effective: progression-free survival (PFS) 9.1 months (range: 0.9-39.2+) overall (OS) 9.6 (range 3-41.5+). Conclusions: therapy proved feasible safe. PFS OS data are encouraging as benefit due bevacizumab's high capacity provide long-lasting decrease perilesional edema.